The Aporphine Alkaloid Dicentrine and Its N-Oxide Derivatives Inhibit Akt Pathway in Head and Neck Cancer Cell Lines and Induce Anti-Inflammatory Response Independent of TP53 Status

Abstract Head and neck squamous cancers (HNSC) are a group of heterogeneous tumors that frequently have TP53 mutations associated with a worse prognosis and poor response to treatment. Current therapy combines chemotherapy and radiotherapy for both early and advanced diseases, underscoring the need for new drugs to improve conventional therapy. In recent years, natural product research has increasingly focused on the discovery and development of anticancer agents. Dicentrine (1), for example, is an aporphine alkaloid isolated from the leaves of Ocotea puberula. Dicentrine and its N-oxide derivatives (compounds 1a and 1b) have demonstrated cytotoxic activity against tumor cells, highlighting their potential as bioactive natural-product scaffolds. As a continuation of our studies, the present work investigated the antitumor potential of compounds 1, 1a, and 1b in head and neck squamous cell carcinoma (HNSCC) cell lines with distinct TP53 statuses, namely, FaDu (TP53 mutant) and SCC143 (TP53 wild-type) cells. In vitro studies through cell viability, colony formation assay, cell death, and in silico analysis through molecular docking and molecular dynamics simulations demonstrated that compound 1b has lost its antitumor activity, while compounds 1 and 1a inhibited colony formation, decreased cell viability, and induced cell death independently of TP53 status. We also demonstrated that compounds 1 and 1a decreased HMGB1, IL18, and Akt expression. Our in silico analysis suggested that compounds 1 and 1a adopt a productive binding mode at the AKT1 kinase, whereas p53 is not a stable target. Such findings provide additional evidence for the use of compounds 1 and 1a as therapeutic drugs also for head and neck cancer.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-12
DOI
https://doi.org/10.1021/acsomega.6c10724
Primary Topic
Berberine and alkaloids research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Aporphine Alkaloid Dicentrine and Its N-Oxide Derivatives Inhibit Akt Pathway in Head and Neck Cancer Cell Lines and Induce Anti-Inflammatory Response Independent of TP53 Status

Giselle Cerchiaro, João Henrique G. Lago, Natália Meneses Araújo, Ranyelison Silva Machado et al.
ACS Omega
Berberine and alkaloids research
article

The Aporphine Alkaloid Dicentrine and Its N-Oxide Derivatives Inhibit Akt Pathway in Head and Neck Cancer Cell Lines and Induce Anti-Inflammatory Response Independent of TP53 Status

Giselle Cerchiaro, João Henrique G. Lago, Natália Meneses Araújo, Ranyelison Silva Machado, Rodrigo Esaki Tamura, Daniela C. Tristão, Giovanna Barbosa Chanes, Laura Maria Pinto Dias, Augusto Batista Farias, Kaio de Souza Gomes, Ileana Gabriela Sanchez de Rubio
article en

Abstract

Abstract Head and neck squamous cancers (HNSC) are a group of heterogeneous tumors that frequently have TP53 mutations associated with a worse prognosis and poor response to treatment. Current therapy combines chemotherapy and radiotherapy for both early and advanced diseases, underscoring the need for new drugs to improve conventional therapy. In recent years, natural product research has increasingly focused on the discovery and development of anticancer agents. Dicentrine (1), for example, is an aporphine alkaloid isolated from the leaves of Ocotea puberula. Dicentrine and its N-oxide derivatives (compounds 1a and 1b) have demonstrated cytotoxic activity against tumor cells, highlighting their potential as bioactive natural-product scaffolds. As a continuation of our studies, the present work investigated the antitumor potential of compounds 1, 1a, and 1b in head and neck squamous cell carcinoma (HNSCC) cell lines with distinct TP53 statuses, namely, FaDu (TP53 mutant) and SCC143 (TP53 wild-type) cells. In vitro studies through cell viability, colony formation assay, cell death, and in silico analysis through molecular docking and molecular dynamics simulations demonstrated that compound 1b has lost its antitumor activity, while compounds 1 and 1a inhibited colony formation, decreased cell viability, and induced cell death independently of TP53 status. We also demonstrated that compounds 1 and 1a decreased HMGB1, IL18, and Akt expression. Our in silico analysis suggested that compounds 1 and 1a adopt a productive binding mode at the AKT1 kinase, whereas p53 is not a stable target. Such findings provide additional evidence for the use of compounds 1 and 1a as therapeutic drugs also for head and neck cancer.

ACS Omega
Universidade de São Paulo (BR), Universidade Federal do ABC (BR), Universidade Federal de São Paulo (BR)
Fundação de Amparo à Pesquisa do Estado de São Paulo, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico
Good health and well-being
Berberine and alkaloids research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon